Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 NeuroDerm Bought for $1.1B | Contract Pharma

What are you searching for?

Sign in
Breaking News

NeuroDerm Bought for $1.1B

Mitsubishi Tanabe Pharma Corporation acquires lead Phase III Parkinson’s candidate

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Mitsubishi Tanabe Pharma Corporation is acquiring Israeli pharma firm NeuroDerm for $1.1 billion. NeuroDerm is a clinical stage company developing drug-device combinations for central nervous system (CNS) disorders. The deal is expected to close in the fourth quarter of 2017.

“We believe that this transaction will yield important benefits for NeuroDerm’s shareholders and the Parkinson’s disease patients that urgently need new therapies,” said Oded Lieberman, chief executive officer, NeuroDerm. “MTPC has demonstrated development and commercialization expertise in the field of neurology and we are confident that the combination of their resources and the robust data supporting ND0612, our Phase III Parkinson’s disease product candidate, will help make this important new therapy available as broadly and rapidly as possible.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics